The US Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) Injection 8mg, submitted by US biotech ...

Australian clinical-stage biotech Neurizon Therapeutics (ASX: NUZ & NUZOA), which is advancing innovative treatments for ...

UK pharma major GSK on Friday announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has licensed Blenrep (belantamab mafodotin) in combinations with bortezomib plus ...

US biopharma company Galmed Pharmaceuticals has entered into a research collaboration with Virginia Commonwealth University to investigate its lead candidate Aramchol (arachidyl amido cholanoic acid) ...

BigHat Biosciences, a Californian biotech with a machine learning (ML)-guided antibody discovery and development platform, ...

US cancer drug developer Werewolf Therapeutics today announced the appointment of Steven Bloom as chief business officer ...

Orforglipron is the first oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food and water ...

Florida biopharma Ligand Pharmaceuticals subsidiary Pelthos Therapeutics is to merge with Channel Therapeutics (NYSE American ...

Swiss pharma major Novartis has discontinued development of its experimental treatment QUC398 for knee osteoarthritis, ending ...

India’s Venus Remedies has secured Qualified Infectious Disease Product designation from the United States Food and Drug ...

Indian drugmaker Biocon (BSE: 532523) subsidiary Biocon Biologics has announced a settlement and license agreement with the ...

Germany’s Evotec has unveiled a new strategy, and provided 2025 guidance—bolstered by strong results from the fourth-quarter of 2024.